News

The company has already completed galeterone Phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The funding has been granted by Novartis

The trial aims to assess the impact of the drug on menstrual events, as well as liver function. In the trial, the patients will be administered with 12mg

TCN-032 was discovered utilizing Theraclone’s I-STAR platform. The trial aims to investigate the safety profile of a single intravenous administration of TCN-032 compared to placebo. The study expects

The company has also opened an additional study and recruiting patients at the Stanford University Medical Center in Palo Alto, CA. The study aims to investigate safety and

In his new role, Adams will be responsible for strengthening the company’s R&D operations and commercial infrastructures to support NLX-P101. Prior to joining Neurologix, Adams worked as the

The agreement allows CMC Biologics to manufacture bulk IB1001, Inspiration’s intravenous recombinant factor IX (rFIX) product, for at least six years. Further details of the agreement were not

The earlier studies, which included previously untreated genotype-1 chronic HCV patients and the patients who failed previous treatment, showed improvements in cure rates when treated with telaprevir in

The deal includes a two-year research collaboration with Chun-Ming Huang and his associates at UC San Diego School of Medicine for further research and development. Further, the financial

Burns has held executive management positions at Renishaw Diagnostics, Cyntellect, GE Healthcare, Imaging Research, BioSignal Packard, and Pharmacia / LKB. Cellectricon chairman Axel Broms said they are looking